TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05211973

Intervention type: DEVICE
Intervention: Wrist Actigraphy Device
Description: a watch like wearable sensor

Intervention type: DEVICE
Intervention: Wrist Actigraphy Device
Description: a watch like wearable sensor

Intervention type: DEVICE
Intervention: Wrist Actigraphy Device
Description: a watch like wearable sensor

Intervention type: DEVICE
Intervention: Smart Body Weight Scale
Description: a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)

Intervention type: DEVICE
Intervention: Smart Body Weight Scale
Description: a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)

Intervention type: DEVICE
Intervention: Smart Body Weight Scale
Description: a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)

Intervention type: DEVICE
Intervention: Chair Scale
Description: a wheel-chair compatible scale to measure body weight

Intervention type: DEVICE
Intervention: Chair Scale
Description: a wheel-chair compatible scale to measure body weight

Intervention type: DEVICE
Intervention: Chair Scale
Description: a wheel-chair compatible scale to measure body weight
Study: NCT05420077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVM-V001 10 µg
Description: Low Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVM-V001 30 µg
Description: Mid Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVM-V001 60 µg
Description: High Dose
Study: NCT05211973

Intervention type: DEVICE
Intervention: Handheld Body Fat Percentage Device
Description: a handheld device that measures body fat percentage

Intervention type: DEVICE
Intervention: Handheld Body Fat Percentage Device
Description: a handheld device that measures body fat percentage

Intervention type: DEVICE
Intervention: Handheld Body Fat Percentage Device
Description: a handheld device that measures body fat percentage
Study: NCT05062798

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standart bottle
Description: 1. After the surgery, standard bottle will be used for feeding.~2. Following the completion of the surgery,feeding process evaluation will be performed until the discharge by using the feeding evaluation form.~3. Patients will be given a follow-up appointment 2 weeks after the operation and a feeding process evaluation will be made.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Squeezable bottle
Description: 1. After the surgery, squeezable bottle will be used for feeding.~2. Following the completion of the surgery,feeding process evaluation will be performed until the discharge by using the feeding evaluation form.~3. Patients will be given a follow-up appointment 2 weeks after the operation and a feeding process evaluation will be made.
Study: NCT05205005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocalyx
Description: 3,712mg (six capsules) of DSGP for eight weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ingredients per capsule (6 capsules per day) Nu-Mag Nat 10.00mg Rice Flour White 830 mg Magnesium Stearate 10.00mg
Study: NCT05211973

Intervention type: DEVICE
Intervention: Bioelectric Impedance Analysis Scale
Description: a research-grade full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)
Study: NCT05571540

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: U-CAR-T Cells (LstCAR019)
Description: LstCAR019 will be administered by vein. The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set:Dose level one: 1×10\^6 cells/kg;Dose level two: 2×10\^6 cells/kg;Dose level three: 5×10\^6 cells/kg. Each dose group requires at least three subjects. The trial will start from dose level one. The second portion includes a dosage extended cohort and will start after the finish of the3+3dose escalation study. Twelve subjects will get infusion of LstCAR019 at the best dose verified in the first portion.
Study: NCT05837819

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Lighting Intervention
Description: Lighting intervention using high light levels designed to effect the circadian system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Lighting Intervention
Description: Lighting intervention using low light levels designed to not effect the circadian system
Study: NCT04994795

Intervention type: OTHER
Intervention: Predictive models (data collection)
Description: Machine learning predictive models
Study: NCT05837819

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control Lighting Intervention
Description: Lighting intervention using low light levels designed to not effect the circadian system
Study: NCT06243809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg Oral Tablet
Description: Linagliptin 5 mg Oral Tablet
Study: NCT05211973

Intervention type: DEVICE
Intervention: Bioelectric Impedance Analysis Scale
Description: a research-grade full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)

Intervention type: DEVICE
Intervention: Bioelectric Impedance Analysis Scale
Description: a research-grade full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)
Study: NCT06284460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX029
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX029
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Given by PO
Study: NCT04883099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APIOC for Presbyopia and APIOC for Presbyopia for Astigmatism
Description: Contact Lenses for Presbyopia
Study: NCT05885373

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SIM01
Description: SIM01 consists of a blend of food-grade Bifidobacterium as active probiotics
Study: NCT06071793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family involvement
Description: Family delivery of mobility activities
Study: NCT05294497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand (UB) filtered, non-menthol or menthol cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand (UB) filtered, non-menthol or menthol cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand (UB) filtered, non-menthol or menthol cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand (UB) filtered, non-menthol or menthol cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand (UB) filtered, non-menthol or menthol cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand (UB) filtered, non-menthol or menthol cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Flavor variant P1312914 of a nicotine pouch product with 4 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Flavor variant P1312914 of a nicotine pouch product with 4 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Flavor variant P1312914 of a nicotine pouch product with 4 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Flavor variant P1312914 of a nicotine pouch product with 4 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Flavor variant P1312914 of a nicotine pouch product with 4 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Flavor variant P1312914 of a nicotine pouch product with 4 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: Flavor variant P1312915 of a nicotine pouch product with 8 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: Flavor variant P1312915 of a nicotine pouch product with 8 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: Flavor variant P1312915 of a nicotine pouch product with 8 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: Flavor variant P1312915 of a nicotine pouch product with 8 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: Flavor variant P1312915 of a nicotine pouch product with 8 mg of nicotine
Study: NCT05550857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eccentric resistance exercise
Description: The subject will lying prone on a treatment table. One end of eccentric resistance band will tie around the mid of the foot of indvidual, the other end of the resistance band will be attach to the table and the band is adjusted so that it will tight and there will be no slack present in it. It will provide a smooth eccentric resistance throughout the dorsiflexion range
Study: NCT05294497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: Flavor variant P1312915 of a nicotine pouch product with 8 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: Flavor variant P1313014 of a nicotine pouch product with 4 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: Flavor variant P1313014 of a nicotine pouch product with 4 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: Flavor variant P1313014 of a nicotine pouch product with 4 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: Flavor variant P1313014 of a nicotine pouch product with 4 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: Flavor variant P1313014 of a nicotine pouch product with 4 mg of nicotine
Study: NCT05550857

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: myofascial release
Description: The subject will lye prone on a treatment table. Deep longitudinal massage with the help of both thumbs reinforcing eachother will be given on the subject's calf muscles.
Study: NCT05294497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: Flavor variant P1313014 of a nicotine pouch product with 4 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum
Study: NCT06243809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin 5 mg Oral Tablet
Description: Linagliptin 5 mg Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trajenta 5 MG Oral Tablet
Description: Linagliptin 5 mg Oral Tablet (Trajenta )

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trajenta 5 MG Oral Tablet
Description: Linagliptin 5 mg Oral Tablet (Trajenta )
Study: NCT06306040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine Versus Magnesium Sulfate
Description: Nalbuphine is a synthetic opioid receptor agonist-antagonist (agonist К receptor, antagonistic part μ receptor) that can produce a central analgesic effect and partial sedation. Nalbuphine is a medication that is indicated for moderate to severe pain where the patient requires an opioid agent, and other alternative treatments have been insufficient. The inhibitory effect of nalbuphine on respiration is slight and it has a capping effect. Owing to these advantages, it is widely used in pediatric surgical analgesia.~Magnesium sulphate, an antagonist of N-methyl-D-aspartate (NMDA) glutamate receptors, has been reported to improve hypo-magnesia and pre-eclampsia. Recently, magnesium sulphate has been gradually used as an adjuvant for sedation and analgesia during general anesthesia. Magnesium sulphate is a medication used to manage and treat multiple clinical conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine Versus Magnesium Sulfate
Description: Nalbuphine is a synthetic opioid receptor agonist-antagonist (agonist К receptor, antagonistic part μ receptor) that can produce a central analgesic effect and partial sedation. Nalbuphine is a medication that is indicated for moderate to severe pain where the patient requires an opioid agent, and other alternative treatments have been insufficient. The inhibitory effect of nalbuphine on respiration is slight and it has a capping effect. Owing to these advantages, it is widely used in pediatric surgical analgesia.~Magnesium sulphate, an antagonist of N-methyl-D-aspartate (NMDA) glutamate receptors, has been reported to improve hypo-magnesia and pre-eclampsia. Recently, magnesium sulphate has been gradually used as an adjuvant for sedation and analgesia during general anesthesia. Magnesium sulphate is a medication used to manage and treat multiple clinical conditions.
Study: NCT05819424

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yeast Fermentate (EpiCor)
Description: Dietary Supplement: Yeast Fermentate (EpiCor): Postbiotic whole food fermentate made using yeast. Composed of proteins, polyphenols, vitamins, minerals, amino acids, polysaccharides, fibre, and other nutrients.~Placebo: Substance with no therapeutic value to facilitate blinding

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yeast Fermentate (EpiCor)
Description: Dietary Supplement: Yeast Fermentate (EpiCor): Postbiotic whole food fermentate made using yeast. Composed of proteins, polyphenols, vitamins, minerals, amino acids, polysaccharides, fibre, and other nutrients.~Placebo: Substance with no therapeutic value to facilitate blinding
Study: NCT06306040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine Versus Magnesium Sulfate
Description: Nalbuphine is a synthetic opioid receptor agonist-antagonist (agonist К receptor, antagonistic part μ receptor) that can produce a central analgesic effect and partial sedation. Nalbuphine is a medication that is indicated for moderate to severe pain where the patient requires an opioid agent, and other alternative treatments have been insufficient. The inhibitory effect of nalbuphine on respiration is slight and it has a capping effect. Owing to these advantages, it is widely used in pediatric surgical analgesia.~Magnesium sulphate, an antagonist of N-methyl-D-aspartate (NMDA) glutamate receptors, has been reported to improve hypo-magnesia and pre-eclampsia. Recently, magnesium sulphate has been gradually used as an adjuvant for sedation and analgesia during general anesthesia. Magnesium sulphate is a medication used to manage and treat multiple clinical conditions.
Study: NCT04994795

Intervention type: OTHER
Intervention: Predictive models (data collection)
Description: Machine learning predictive models

Intervention type: OTHER
Intervention: Predictive models (data collection)
Description: Machine learning predictive models
Study: NCT05014035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: This is an 8-week exercise program, delivered using a hybrid approach of in-person, in-home supervised exercise, and virtual delivery of exercise via zoom. Individuals will participate in resistance exercise 3 days per week for 8 weeks.
Study: NCT04623554

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prehabilitation program
Description: The prehabilitation program includes combined high-intensity interval training on a cycle ergometer and machine-based resistance exercise of large muscle groups supervised by a physiotherapist. Exercise sessions will take place in physiotherapy departments at local hospitals or in municipality rehabilitation centres 3 times a week during the neoadjuvant chemotherapy period and ending in the week before breast surgery (maximum estimated 29 weeks depending on number of chemotherapy cycles, dose delays and time of breast surgery). Participants will be screened for psychological distress four times and in case of moderate-severe distress be advised to visit the local Cancer Society Support Center where participants will be assessed and offered free services based on their psychosocial needs and available offers. Participation will be monitored.
Study: NCT05294497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: Flavor variant P1313015 of a nicotine pouch product with 8 mg of nicotine
Study: NCT04897633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial electric stimulation
Description: Simon's task assessment when under tDCS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial electric stimulation
Description: Simon's task assessment when under tDCS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial electric stimulation
Description: Simon's task assessment when under tDCS
Study: NCT05212467

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AIR-program
Description: This is a guided self management program that is added on the treatment as usual.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HUS Internet therapy
Description: This is a guided self management program that is added on the treatment as usual.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The patients receive routine care from their physician which may include drugs, visits or rehabilitation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The patients receive routine care from their physician which may include drugs, visits or rehabilitation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: The patients receive routine care from their physician which may include drugs, visits or rehabilitation
Study: NCT05294497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: Flavor variant P1313015 of a nicotine pouch product with 8 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: Flavor variant P1313015 of a nicotine pouch product with 8 mg of nicotine
Study: NCT06381050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-7631
Description: The total dosage of SHR-7631 was calculated according to the weight weighing results of the subjects before each administration, and was administered by intravenous drip.
Study: NCT05575024

Intervention type: DEVICE
Intervention: oXiris membrane
Description: Perform continuous renal replacement therapy with oXiris membrane

Intervention type: DEVICE
Intervention: Polysulfone membrane
Description: Perform continuous renal replacement therapy with polysulfone membrane
Study: NCT05294497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: Flavor variant P1313015 of a nicotine pouch product with 8 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: Flavor variant P1313015 of a nicotine pouch product with 8 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: Flavor variant P1313015 of a nicotine pouch product with 8 mg of nicotine
Study: NCT06396689

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic
Description: The capsule contains Lactobacillus helveticus R0052, Bifidobacterium infantis R0033, and Bifidobacterium bifidum R0071 (3 billion bacteria per capsule), as well as zinc oxide, potato starch fructooligosaccharides, coating agent, methyl hydroxypropyl cellulose, anti-caking agent and magnesium stearat
Study: NCT06253455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tested product
Description: application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tested product
Description: application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tested product
Description: application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
Study: NCT06179810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Description: Baduanjin exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Description: Baduanjin exercise
Study: NCT04776616

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Exposure to white LED light
Description: Participants will be exposed to white LED strip lights in a dark room for 2 hours a day
Study: NCT05783843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pictorial Warnings
Description: Participants will be shown 6 waterpipe tobacco packages with 6 different pictorial warnings about the health harms of waterpipe smoking. The order of the 6 packages within this trial arm will be randomized. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study and designed the warnings for this arm.
Study: NCT04776616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exposure to green LED light
Description: Participants will be exposed to green LED strip lights in a dark room for 2 hours a day
Study: NCT04520152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeFlowMedical Lung Tensioning Device
Description: Bronchoscopic lung tensioning device implantation
Study: NCT05783843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Warnings
Description: Participants will be shown 6 waterpipe tobacco packages with 6 different text-only warnings about the health harms of waterpipe smoking. The order of the 6 packages within this trial arm will be randomized. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study and designed the warnings for this arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Warnings (Control)
Description: Participants will be shown a single package without a warning. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study.